CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Ironwood
Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the appointment
of Amy Schulman to its board of directors. Schulman is an accomplished
leader and entrepreneur with a proven track record of enabling
pharmaceutical and biotechnology companies to maximize the value of
their brands and realize the potential of their innovations. She
currently holds key leadership roles at two biotech companies, serving
as chief executive officer and co-founder of Lyndra, Inc., and executive
chair of SQZ Biotech. In addition, she is a venture partner at Polaris
Partners, serving on the firm's life sciences investment team.
"Ironwood is committed to attracting board members who have an
owner-oriented mindset, business savvy, a strong interest in our
company, absolute integrity and great strategic judgment. We believe Amy
embodies each of these qualities, and that she will be a valuable
advisor as we seek to expand the reach and impact of our marketed
products, advance our internal pipeline, and identify opportunities to
access external innovation," said Peter Hecht, chief executive officer
of Ironwood.
"Ironwood has successfully advanced an innovative product to market and
established a strong commercial capability, which is driving revenue
growth and pipeline development," said Schulman. "This is how innovative
biopharmaceutical companies are created, and it is an honor to join this
Board as we help the terrific management team bring value for patients
and shareholders."
In addition to her roles at Lyndra, SQZ, and Polaris, Schulman is also a
senior lecturer at Harvard Business School and serves on the boards of
directors of Alnylam Pharmaceuticals, Inc. and Blue Buffalo Pet
Products, Inc. She also recently served as chief executive officer of
Arsia Therapeutics, Inc., until its acquisition in November 2016. Prior
to these roles, she was the executive vice president and general counsel
of Pfizer Inc. In this role, she led the $4 billion consumer healthcare
business, including the Advil, Chapstick, Centrum, Emergen-C, and
Robitussin brands, while concurrently acting as general counsel and
leading the company's team of approximately 700 legal professionals as
well as participating on the company's executive leadership team.
Previously, she held the position of senior vice president and general
manager of Pfizer Nutrition. Before joining Pfizer, she was a partner at
the law firm DLA Piper, where she was a member of the board and
executive policy committees. Schulman graduated with honors from
Wesleyan University, where she was elected to Phi Beta Kappa, and earned
her J.D. from Yale Law School.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology
company focused on creating medicines that make a difference for
patients, building value for our fellow shareholders, and empowering our
passionate team. We are advancing a pipeline of innovative medicines in
areas of significant unmet need, including irritable bowel syndrome with
constipation (IBS-C)/chronic idiopathic constipation (CIC), uncontrolled
gout, refractory gastroesophageal reflux disease, and vascular and
fibrotic diseases. We discovered, developed and are commercializing
linaclotide, the U.S. branded prescription market leader in the
IBS-C/CIC category, and we are applying our proven R&D and commercial
capabilities to advance multiple internally-developed and
externally-accessed product opportunities. Ironwood was founded in 1998
and is headquartered in Cambridge, Mass. For more information, please
visit www.ironwoodpharma.com
or www.twitter.com/ironwoodpharma;
information that may be important to investors will be routinely posted
in both these locations.
This press release contains forward-looking statements. Investors are
cautioned not to place undue reliance on these forward-looking
statements, including statements about the expected benefits from Ms.
Schulman's service on the Company's board, expanding the reach and
impact of our marketed products, advancing our internal pipeline,
identifying opportunities to access external innovation, and driving
revenue growth and pipeline development. Each forward-looking
statement is subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in such
statement. Applicable risks and uncertainties include those related to
the effectiveness of commercialization efforts by us and our partners;
preclinical and clinical development, manufacturing and formulation
development; the risk that findings from our completed nonclinical and
clinical studies may not be replicated in later studies; efficacy,
safety and tolerability of linaclotide, lesinurad and our product
candidates; decisions by regulatory authorities; the risk that we may
never get sufficient patent protection for linaclotide and our product
candidates or that we are not able to successfully protect such patents;
developments in the intellectual property landscape; challenges from and
rights of competitors or potential competitors; the risk that our
planned investments do not have the anticipated effect on our company
revenues, linaclotide, lesinurad or our product candidates; and the
risks listed under the heading "Risk Factors" and elsewhere in
Ironwood's Quarterly Report on Form 10-Q for the quarter ended
September 30, 2016, and in our subsequent SEC filings. These
forward-looking statements (except as otherwise noted) speak only as of
the date of this press release, and Ironwood undertakes no obligation to
update these forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170104005511/en/
Ironwood Pharmaceuticals, Inc.
Media Relations
Trista
Morrison, 617-374-5095
Director, Corporate Communications
tmorrison@ironwoodpharma.com
or
Investor
Relations
Meredith Kaya, 617-374-5082
Director, Investor
Relations
mkaya@ironwoodpharma.com
Source: Ironwood Pharmaceuticals, Inc.
News Provided by Acquire Media